Hematopoietic stem cell transplantation in the elderly

ONCOLOGY

Volumn 21, Issue 13, 2007, Pages 1576-1583

  Ballester, Gabriela ^a   Tirona, Maria Tria ^a   Ballester, Oscar ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; THIOTEPA; TOSITUMOMAB I 131; CD34 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CARDIOTOXICITY; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DONOR SELECTION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ELDERLY CARE; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NONHODGKIN LYMPHOMA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; STEM CELL MOBILIZATION; THROMBOCYTHEMIA; TREATMENT RESPONSE; WHOLE BODY RADIATION; AGE; AGED; ANIMAL; BLOOD; COMORBIDITY; LYMPHATIC LEUKEMIA; MORTALITY; REVIEW; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD34; COMORBIDITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 40449110070     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Balducci L, Hardy C, Lyman G: Hematopoiesis and aging. Cancer Treat Res 124:189-221, 2005.
2. Xing Z, Ryan M, Daria D, et al: Increased hematopoietic stem cell mobilization in aged mice. Blood 108:2190-2197, 2006.
3. Liang Y, Van Zant G, Szilvassy S: Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 106:1479-1487, 2005.
4. Moresi R, Tesei S, Costarelli L, et al: Age- and gender-related alterations of the number and clonogenic capacity of circulating CD 34+ progenitor cells. Biogerontology 6:185-192, 2005.
5. Chatta G, Price T, Allen R, et al: Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84:2923-2929, 1994.
6. Klaus J, Herrmann D, Breitkreutz I, et al: Effect of CD 34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 78:21-28, 2006.
7. Morris C, Siegel E, Barlogie B, et al: Mobilization of CD 34+ cells in elderly patients (≥ 70 years) with multiple myeloma: Influence of age, prior therapy, platelets count and mobilization regimen. Br J Haematol 120:413-423, 2003.
8. de la Rubia J, Blade J, Lahuerta J, et al: Effect of chemotherapy with alkylating agents on the yield of CD 34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 91:621-627, 2006.
9. Ferrara F, Viola A, Copia C, et al: Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. Hematol Oncol 25:84-89, 2007.
10. Kollman C, Howe C, Anasetti C, et al: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98:2043-2051, 2001.
11. Kusnierz-Glaz CR, Schlegel PG, Schriber R, et al: Influence of age on the outcome of 500 autologous marrow transplant procedures for hematological malignancies. J Clin Oncol 15:18-25, 1997.
12. Mileshkin LR, Seymour JF, Wolf MM, et al: Cardiovascular toxicity is increased, but mananeable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 46: 1575-1579, 2005.
13. Mazza P, Palazzo G, Amurri B, et al: Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report. Bone Marrow Transplant 23:1273-1278, 1999.
14. Jantunen E, Mahlamaki E, Nousiainen T: Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patiens (>60 years) with non-Hodgkin's lymphoma: Comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 2000; 26:737-741.
15. 2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37:917-922, 2006.
16. Badros A, Barlogie B, Siegel E, et al: Autologous Stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114:600-607, 2001.
17. Gopal AK, Gooley TA, Golden JB, et al: Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 27:593-599, 2001.
18. Olivieri A, Capelli D, Montanari M, et al: Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: A single center experience. Bone Marrow Transplant 27:1189-1195, 2001.
19. Yanada M, Emi N, Naoe T, et al: Allogeneic myeloablative transplantation for patients aged 50 year and over. Bone Marrow Transplant 34:29-35, 2004.
20. Aylea EP, Kim HT, Ho V, et al: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105:1810-1814, 2005.
21. Scott BL, Sandmaier BM, Storer B, et al: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic sendrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20:128-135, 2006.
22. Aoudihane M, Labopin M, Gorin NC, et al: Comparative outcome od reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation. Leukemia 19:2304-2312, 2005.
23. Canals C, Martino R, Sureda A, et al: Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 31:1039-1043, 2003.
24. Corradini P, Zallio F, Mariotti J, et al: Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 23:6690-6698, 2005.
25. Gómez-Núñez M, Martino R, Caballero MD, et al: Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial. Bone Marrrow Transplant 33:477-482, 2004.
26. Sorror M, Maris M, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005.
27. Giles F, Borthakur G, Ravandi F, et al: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007.
28. Kassar M, Gregory S, Shell K, et al: Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma (abstract 7102). J Clin Oncol 25(18S):382s, 2007.
29. Ferrara F, Palmieri S, Clementano M, et al: Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leuk Lymphoma 47:1593-1598, 2006.
30. Oriol A, Ribera J, Esteve J, et al: Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Hematologica 89:791-800, 2004.
31. Thomas X, Suciu S, Rio B, et al: Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: Results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 92:389-396, 2007.
32. Gorin N, Labopin M, Pichard P, et al: Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: Importance of the source of stem cells. Br J Haematol 110:887-893, 2000.
33. Deeg H, Shulman H, Anderson J, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188-1194, 2000.
34. Gupta V, Daly A, Lipton J, et al: Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11:764-772, 2005.
35. Niederwieser D, Becker C, Krahl R, et al: Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to chemotherapy (OSHO 97 study) (abstract 7003). J Clin Oncol 25(18S):357s, 2007.
36. Hamaki T, Kami M, Kanda Y, et al: Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: A retrospective study of 33 patients. Bone Marrow Transplant 35:549-556, 2005.
37. Siegel DS, Desikan KR, Mehta J, et al: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1:51-54, 1999.
38. Reece DE, Bredeson C, Perez WS, et al: Autologous stem cell transplantation in multiple myeloma patients <60 vs >60 years of age. Bone Marrow Trasplant 32:1135-1143, 2003.
39. Lenhoff S, Hjorth M, Westin J, et al: Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol 133:389-396, 2006.
40. Gertz MA, Lacy MQ, Dispenzieri A, et al: Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 39:605-611, 2007.
41. Badros A, Barlogie B, Siegel E, et al: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114:600-607, 2001.
42. Arora M, McGlave PB, Burns LJ, et al: Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 35:1133-1140, 2005.
43. Crawley C, Iacobelli S, Bjorkstrand B, et al: Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109:3588-3594, 2007.
44. Bruno B, Rotta M, Patriarca F, et al: A comparison of allorafting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110-1120, 2007.
45. Jantunen E, Hala M, Juvonen E, et al: Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: A nation-wide analysis. Bone Marrow Transplant 37:367-372, 2006.
46. Gopal AK, Rajendran JG, Gooley TA, et al: High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25:1396-1402, 2007.
47. Bitran JD, Klein L, Link D, et al: High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 9:383-388, 2003.
48. Seldin DC, Anderson JJ, Skinner M, et al: Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108:3945-3947, 2006.
49. Brown JR, Kim HT, Stephans K, et al: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056-1064, 2006.
50. Kerbauy DMB, Gooley TA, Sale GE, et al: Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocytemia. Biol Blood Marrow Transpant 13:355-365, 2007.